Proactiveinvestors USA & Canada Tissue Regenix Group PLC https://www.proactiveinvestors.com Proactiveinvestors USA & Canada Tissue Regenix Group PLC RSS feed en Thu, 18 Jul 2019 01:42:29 -0400 http://blogs.law.harvard.edu/tech/rss Genera CMS action@proactiveinvestors.com (Proactiveinvestors) action@proactiveinvestors.com (Proactiveinvestors) <![CDATA[RNS press release - Holding(s) in Company ]]> https://www.proactiveinvestors.com/companies/rns/3008/LSE20190708170303_14140678/ Mon, 08 Jul 2019 12:03:03 -0400 https://www.proactiveinvestors.com/companies/rns/3008/LSE20190708170303_14140678/ <![CDATA[RNS press release - Result of AGM ]]> https://www.proactiveinvestors.com/companies/rns/3008/LSE20190627105113_14127100/ Thu, 27 Jun 2019 05:51:13 -0400 https://www.proactiveinvestors.com/companies/rns/3008/LSE20190627105113_14127100/ <![CDATA[RNS press release - Issue of Equity and Total Voting Rights ]]> https://www.proactiveinvestors.com/companies/rns/3008/LSE20190607145528_14103596/ Fri, 07 Jun 2019 09:55:28 -0400 https://www.proactiveinvestors.com/companies/rns/3008/LSE20190607145528_14103596/ <![CDATA[RNS press release - Notice of AGM ]]> https://www.proactiveinvestors.com/companies/rns/3008/LSE20190604070012_14097078/ Tue, 04 Jun 2019 02:00:12 -0400 https://www.proactiveinvestors.com/companies/rns/3008/LSE20190604070012_14097078/ <![CDATA[RNS press release - Annual Results for the year ended 31 December 2018 ]]> https://www.proactiveinvestors.com/companies/rns/3008/LSE20190604070009_14097054/ Tue, 04 Jun 2019 02:00:09 -0400 https://www.proactiveinvestors.com/companies/rns/3008/LSE20190604070009_14097054/ <![CDATA[RNS press release - CEO to return to full time duties ]]> https://www.proactiveinvestors.com/companies/rns/3008/LSE20190521070024_14080992/ Tue, 21 May 2019 02:00:24 -0400 https://www.proactiveinvestors.com/companies/rns/3008/LSE20190521070024_14080992/ <![CDATA[RNS press release - Expands US GPO coverage for DermaPure ]]> https://www.proactiveinvestors.com/companies/rns/3008/LSE20190404072643_14028629/ Thu, 04 Apr 2019 02:26:43 -0400 https://www.proactiveinvestors.com/companies/rns/3008/LSE20190404072643_14028629/ <![CDATA[RNS press release - Change of Adviser ]]> https://www.proactiveinvestors.com/companies/rns/3008/LSE20190218070014_13972328/ Mon, 18 Feb 2019 02:00:14 -0500 https://www.proactiveinvestors.com/companies/rns/3008/LSE20190218070014_13972328/ <![CDATA[RNS press release - Second Price Monitoring Extn ]]> https://www.proactiveinvestors.com/companies/rns/3008/LSE20190206110515_13960365/ Wed, 06 Feb 2019 06:05:15 -0500 https://www.proactiveinvestors.com/companies/rns/3008/LSE20190206110515_13960365/ <![CDATA[RNS press release - Price Monitoring Extension ]]> https://www.proactiveinvestors.com/companies/rns/3008/LSE20190206110018_13960356/ Wed, 06 Feb 2019 06:00:18 -0500 https://www.proactiveinvestors.com/companies/rns/3008/LSE20190206110018_13960356/ <![CDATA[RNS press release - Trading Update ]]> https://www.proactiveinvestors.com/companies/rns/3008/LSE20190204070005_13956310/ Mon, 04 Feb 2019 02:00:05 -0500 https://www.proactiveinvestors.com/companies/rns/3008/LSE20190204070005_13956310/ <![CDATA[RNS press release - Interim Management Change ]]> https://www.proactiveinvestors.com/companies/rns/3008/LSE20181206070009_13893372/ Thu, 06 Dec 2018 02:00:09 -0500 https://www.proactiveinvestors.com/companies/rns/3008/LSE20181206070009_13893372/ <![CDATA[RNS press release - Pan European distribution agreement with Arthrex ]]> https://www.proactiveinvestors.com/companies/rns/3008/LSE20181113070011_13864233/ Tue, 13 Nov 2018 02:00:11 -0500 https://www.proactiveinvestors.com/companies/rns/3008/LSE20181113070011_13864233/ <![CDATA[RNS press release - Gareth Jones commences position as CFO ]]> https://www.proactiveinvestors.com/companies/rns/3008/LSE20181029070007_13845107/ Mon, 29 Oct 2018 03:00:07 -0400 https://www.proactiveinvestors.com/companies/rns/3008/LSE20181029070007_13845107/ <![CDATA[RNS press release - Unaudited Interim Results ]]> https://www.proactiveinvestors.com/companies/rns/3008/LSE20180903070008_13775614/ Mon, 03 Sep 2018 02:00:08 -0400 https://www.proactiveinvestors.com/companies/rns/3008/LSE20180903070008_13775614/ <![CDATA[RNS press release - Notice of Interim Results ]]> https://www.proactiveinvestors.com/companies/rns/3008/LSE20180802070027_13740672/ Thu, 02 Aug 2018 02:00:27 -0400 https://www.proactiveinvestors.com/companies/rns/3008/LSE20180802070027_13740672/ <![CDATA[RNS press release - Appointment of CFO ]]> https://www.proactiveinvestors.com/companies/rns/3008/LSE20180704070005_13704591/ Wed, 04 Jul 2018 02:00:05 -0400 https://www.proactiveinvestors.com/companies/rns/3008/LSE20180704070005_13704591/ <![CDATA[RNS press release - HTA License granted and UK distribution Agreement ]]> https://www.proactiveinvestors.com/companies/rns/3008/LSE20180625070008_13691175/ Mon, 25 Jun 2018 02:00:08 -0400 https://www.proactiveinvestors.com/companies/rns/3008/LSE20180625070008_13691175/ <![CDATA[RNS press release - TRX BioSurgery wins GPO Supplier Horizon Award ]]> https://www.proactiveinvestors.com/companies/rns/3008/LSE20180621071008_13688209/ Thu, 21 Jun 2018 02:10:08 -0400 https://www.proactiveinvestors.com/companies/rns/3008/LSE20180621071008_13688209/ <![CDATA[RNS press release - Issue of Equity ]]> https://www.proactiveinvestors.com/companies/rns/3008/LSE20180618070005_13682643/ Mon, 18 Jun 2018 02:00:05 -0400 https://www.proactiveinvestors.com/companies/rns/3008/LSE20180618070005_13682643/ <![CDATA[RNS press release - Result of AGM ]]> https://www.proactiveinvestors.com/companies/rns/3008/LSE20180524121252_13654272/ Thu, 24 May 2018 07:12:52 -0400 https://www.proactiveinvestors.com/companies/rns/3008/LSE20180524121252_13654272/ <![CDATA[RNS press release - TRX BioSurgery GPO agreement with Premier, Inc. ]]> https://www.proactiveinvestors.com/companies/rns/3008/LSE20180502070014_13626600/ Wed, 02 May 2018 02:00:14 -0400 https://www.proactiveinvestors.com/companies/rns/3008/LSE20180502070014_13626600/ <![CDATA[RNS press release - Posting of Annual Report and Notice of AGM ]]> https://www.proactiveinvestors.com/companies/rns/3008/LSE20180427070134_13620955/ Fri, 27 Apr 2018 02:01:34 -0400 https://www.proactiveinvestors.com/companies/rns/3008/LSE20180427070134_13620955/ <![CDATA[RNS press release - DermaPure manufacturing at CellRight Facility ]]> https://www.proactiveinvestors.com/companies/rns/3008/LSE20180424070006_13615455/ Tue, 24 Apr 2018 02:00:06 -0400 https://www.proactiveinvestors.com/companies/rns/3008/LSE20180424070006_13615455/ <![CDATA[RNS press release - Holding(s) in Company ]]> https://www.proactiveinvestors.com/companies/rns/3008/LSE20180419152934_13611582/ Thu, 19 Apr 2018 10:29:34 -0400 https://www.proactiveinvestors.com/companies/rns/3008/LSE20180419152934_13611582/ <![CDATA[RNS press release - Annual results for period ended 31 December 2017 ]]> https://www.proactiveinvestors.com/companies/rns/3008/LSE20180326070005_13580275/ Mon, 26 Mar 2018 02:00:05 -0400 https://www.proactiveinvestors.com/companies/rns/3008/LSE20180326070005_13580275/ <![CDATA[RNS press release - Publication of Financial Results ]]> https://www.proactiveinvestors.com/companies/rns/3008/LSE20180316154001_13570714/ Fri, 16 Mar 2018 11:40:01 -0400 https://www.proactiveinvestors.com/companies/rns/3008/LSE20180316154001_13570714/ <![CDATA[RNS press release - Hardman & Co: Full-year 2017 - what to look for ]]> https://www.proactiveinvestors.com/companies/rns/3008/LSE20180308071502_13559363/ Thu, 08 Mar 2018 02:15:02 -0500 https://www.proactiveinvestors.com/companies/rns/3008/LSE20180308071502_13559363/ <![CDATA[RNS press release - Long term distribution agreement with Arthrex, Inc ]]> https://www.proactiveinvestors.com/companies/rns/3008/LSE20180306070005_13555628/ Tue, 06 Mar 2018 02:00:05 -0500 https://www.proactiveinvestors.com/companies/rns/3008/LSE20180306070005_13555628/ <![CDATA[RNS press release - Notice of Results ]]> https://www.proactiveinvestors.com/companies/rns/3008/LSE20180226070005_13544994/ Mon, 26 Feb 2018 02:00:05 -0500 https://www.proactiveinvestors.com/companies/rns/3008/LSE20180226070005_13544994/ <![CDATA[RNS press release - Issue of Equity ]]> https://www.proactiveinvestors.com/companies/rns/3008/LSE20180202070004_13519106/ Fri, 02 Feb 2018 02:00:04 -0500 https://www.proactiveinvestors.com/companies/rns/3008/LSE20180202070004_13519106/ <![CDATA[RNS press release - Issue of Equity ]]> https://www.proactiveinvestors.com/companies/rns/3008/LSE20171222093001_13475839/ Fri, 22 Dec 2017 04:30:01 -0500 https://www.proactiveinvestors.com/companies/rns/3008/LSE20171222093001_13475839/ <![CDATA[RNS press release - Directorate Change ]]> https://www.proactiveinvestors.com/companies/rns/3008/LSE20171201070007_13450330/ Fri, 01 Dec 2017 02:00:07 -0500 https://www.proactiveinvestors.com/companies/rns/3008/LSE20171201070007_13450330/ <![CDATA[RNS press release - Issue of Equity ]]> https://www.proactiveinvestors.com/companies/rns/3008/LSE20171201070006_13450291/ Fri, 01 Dec 2017 02:00:06 -0500 https://www.proactiveinvestors.com/companies/rns/3008/LSE20171201070006_13450291/ <![CDATA[RNS press release - Appointment of CEO ]]> https://www.proactiveinvestors.com/companies/rns/3008/LSE20171102070005_13417593/ Thu, 02 Nov 2017 03:00:05 -0400 https://www.proactiveinvestors.com/companies/rns/3008/LSE20171102070005_13417593/ <![CDATA[RNS press release - Directorate Change ]]> https://www.proactiveinvestors.com/companies/rns/3008/LSE20171018070005_13400207/ Wed, 18 Oct 2017 02:00:05 -0400 https://www.proactiveinvestors.com/companies/rns/3008/LSE20171018070005_13400207/ <![CDATA[RNS press release - Hardman Research: Dual revenue stream growth ]]> https://www.proactiveinvestors.com/companies/rns/3008/LSE20171011071501_13392822/ Wed, 11 Oct 2017 02:15:01 -0400 https://www.proactiveinvestors.com/companies/rns/3008/LSE20171011071501_13392822/ <![CDATA[RNS press release - Unaudited Interim Results ]]> https://www.proactiveinvestors.com/companies/rns/3008/LSE20170928151501_13379219/ Thu, 28 Sep 2017 10:15:01 -0400 https://www.proactiveinvestors.com/companies/rns/3008/LSE20170928151501_13379219/ <![CDATA[RNS press release - Notice of Results ]]> https://www.proactiveinvestors.com/companies/rns/3008/LSE20170908070003_13356041/ Fri, 08 Sep 2017 02:00:03 -0400 https://www.proactiveinvestors.com/companies/rns/3008/LSE20170908070003_13356041/ <![CDATA[RNS press release - Notification Of Major Holdings ]]> https://www.proactiveinvestors.com/companies/rns/3008/LSE20170905155255_13352623/ Tue, 05 Sep 2017 10:52:55 -0400 https://www.proactiveinvestors.com/companies/rns/3008/LSE20170905155255_13352623/ <![CDATA[RNS press release - Issue of Equity ]]> https://www.proactiveinvestors.com/companies/rns/3008/LSE20170830171501_13346254/ Wed, 30 Aug 2017 12:15:01 -0400 https://www.proactiveinvestors.com/companies/rns/3008/LSE20170830171501_13346254/ <![CDATA[RNS press release - Holding(s) in Company ]]> https://www.proactiveinvestors.com/companies/rns/3008/LSE20170816122238_13332081/ Wed, 16 Aug 2017 07:22:38 -0400 https://www.proactiveinvestors.com/companies/rns/3008/LSE20170816122238_13332081/ <![CDATA[RNS press release - Holding(s) in Company ]]> https://www.proactiveinvestors.com/companies/rns/3008/LSE20170811154507_13327915/ Fri, 11 Aug 2017 10:45:07 -0400 https://www.proactiveinvestors.com/companies/rns/3008/LSE20170811154507_13327915/ <![CDATA[RNS press release - Holding(s) in Company ]]> https://www.proactiveinvestors.com/companies/rns/3008/LSE20170811153736_13327910/ Fri, 11 Aug 2017 10:37:36 -0400 https://www.proactiveinvestors.com/companies/rns/3008/LSE20170811153736_13327910/ <![CDATA[RNS press release - Holding(s) in Company ]]> https://www.proactiveinvestors.com/companies/rns/3008/LSE20170810163001_13326482/ Thu, 10 Aug 2017 11:30:01 -0400 https://www.proactiveinvestors.com/companies/rns/3008/LSE20170810163001_13326482/ <![CDATA[RNS press release - Holding(s) in Company ]]> https://www.proactiveinvestors.com/companies/rns/3008/LSE20170810144501_13326266/ Thu, 10 Aug 2017 09:45:01 -0400 https://www.proactiveinvestors.com/companies/rns/3008/LSE20170810144501_13326266/ <![CDATA[RNS press release - Hardman Research: CellRight transforming US growth ]]> https://www.proactiveinvestors.com/companies/rns/3008/LSE20170810131003_13326077/ Thu, 10 Aug 2017 08:10:03 -0400 https://www.proactiveinvestors.com/companies/rns/3008/LSE20170810131003_13326077/ <![CDATA[RNS press release - Holding(s) in Company ]]> https://www.proactiveinvestors.com/companies/rns/3008/LSE20170810101002_13325689/ Thu, 10 Aug 2017 05:10:02 -0400 https://www.proactiveinvestors.com/companies/rns/3008/LSE20170810101002_13325689/ <![CDATA[News - Tissue Regenix eyeing European market ]]> https://www.proactiveinvestors.com/companies/news/126269/tissue-regenix-eyeing-european-market-126269.html Regenerative medical technology firm Tissue Regenix Group PLC (LON:TRX) is eyeing a busy year ahead as it expects to bring its dCell technology to the European market within the coming year.

The firm on May 23 reported increased revenue and an increased balance sheet in its financial year to end January, 2016.

The firm's technology removes cellular material from animal and human tissue leaving a 'scaffold' which can then be used to repair diseased or worn out body parts.

Chief executive Antony Odell told investors: "During the year to January, 31, Tissue made significant progress both in the commercialisation and regulatory pathways across all of our key focus areas."

Regeneration is revolutionising treatments

With an ageing population and increasing participation in sports,  the benefits of new methods of treatments that Tissue offers are becoming increasingly clear.

The firm has said the market is expected to reach US$11.5bn by 2022.

It is currently involved in three clinical areas - woundcare, where it has developed DermaPure, which is specifically useful in diabetes, and expects to launch SurgiPure, for the repair of hernias or body wall defects, in the second half of its accounting year.

It also has an orthopaedic side to the business and a cardiac one, where it hopes to bring its heart valves to European patients in the near future through a joint venture.

Dermapure in the US beats expectations

Its woundcare product DermaPure surpassed $1mln of sales in the US, exceeding the group's expectations.

The group's orthopaedic clinical trials are currently ongoing, for both the OrthoPure XM and XT (porcine products), and it anticipate that it will have CE mark (for European commercialisation) approval by early 2017.

"We have also strengthened our senior management team by appointing a VP of Orthopedics for North America, who will be key to guiding our entry into this market over the coming years with both our porcine products and human tissue applications," said Odell.

In final results, the group also highlighted its joint venture in Germany, GBM-V, allowing it to bring the dCELL human tissue applications to a wider European market.

"Also, allowing us to grant for the first time the dCELL heart valve licence and to begin commercialising DermaPure outside the US," said the chief executive.

"Our momentum has accelerated since year end, with further Medicare coverage for DermaPure, and 510(k) market clearance from the FDA for medical device SurgiPure XD, the first approval for a dCELL application under this regulatory body."

In March, US broker Jefferies said it expected further Dermapure sales in the US through 2016/2017.

But it reckoned the orthopedic products - OrthoPure -  will  provide the next leg of growth and will provide meaningful revenues from the first half of the 2017/18 year.

More than 1.5mln people suffer meniscal injuries in the US and EU alone, of which OrthoPure XM would likely target 300,000, it said.

"The other key franchise in the orthopedics portfolio is OrthoPure XT (ACL repair), for which the trial commenced in Dec-15 with first results likely in 1H16/17. The company is on target to launch the human tissue orthopedic products in the US by end-FY16/17," said the broker.

It added "We estimate FY17 Dermapure/ Surgipure sales of $9m/$0.6m, with $2.9m from Orthopure by FY18. We continue to view orthopedics as the greater LT value driver and are encouraged by progress to date."

Jefferies raised the price target to 37p from 36p  - which is more than double the  current shareprice of 17.75p.

Revenue in the year gone grew to £0.8mln from £0.1mln the year before, while the cash balance at year end stood at £19.9mln (£10.3mln).

]]>
Mon, 23 May 2016 10:53:00 -0400 https://www.proactiveinvestors.com/companies/news/126269/tissue-regenix-eyeing-european-market-126269.html
<![CDATA[News - Tissue Regenix Group PLC making progress on all fronts – Jefferies ]]> https://www.proactiveinvestors.com/companies/news/123630/tissue-regenix-group-plc-making-progress-on-all-fronts-jefferies-123630.html Regenerative medtech Tissue Regenix Group PLC (LON:TRX) is making clear progress on all fronts, said heavyweight US broker Jefferies today, which rates the shares a 'buy'.

The group is a wound care expert, with its Dermapure product being used to rebuild cells in the most difficult of wounds.

The broker noted that product (Dermapure ) has now surpassed the $1mln revenue mark and with nine of 11 medicare administrators secured (and promising private payor progress) analyst Chris Cooper expect further acceleration through full year 16/17, particularly now the "hybrid sales model is well established and senior sales directors are in place".

But Jefferies reckons the group's orthopedic products - OrthoPure -  will  provide the next leg of growth and will provide meaningful revenues from the first half of the 2017/18 year.

More than 1.5mln people suffer meniscal injuries in the US and EU alone, of which OrthoPure XM would likely target 300,000, it notes.

"The other key franchise in the orthopedics portfolio is OrthoPure XT (ACL repair), for which the trial commenced in Dec-15 with first results likely in 1H16/17. The company is on target to launch the human tissue orthopedic products in the US by end-FY16/17," added Cooper.

Also significant, the firm was granted last week US regulatory clearance for SurgiPure XD, a skin graft for hernias derived from pig tissue, signalling a commercial launch in the US later this year.

"We estimate FY17 Dermapure/ Surgipure sales of $9m/$0.6m, with $2.9m from Orthopure by FY18. We continue to view orthopedics as the greater LT value driver and are encouraged by progress to date," concluded the analyst.

Jefferies raises the price target to 37p from 36p  - which is more than double the  current share price of 17.5p.

]]>
Mon, 14 Mar 2016 12:23:00 -0400 https://www.proactiveinvestors.com/companies/news/123630/tissue-regenix-group-plc-making-progress-on-all-fronts-jefferies-123630.html